Abro Corporation develops antibody therapies to improve the lives of patients facing severe and life-threatening diseases. Self-described as focused on harnessing the power of the immune system to fight disease.

Abro Corporation

Abpro  | 5,174 followers on LinkedIn. Developing antibody therapies to improve the lives of patients facing severe and life-threatening diseases. | We&#39;re a biotech company dedicated to advancing antibody therapeutics for severe diseases. Focusing on immuno-oncology and ophthalmology, we leverage our proprietary DiversImmune® and MultiMab platforms to develop next-gen antibodies. Collaborating with global pharmaceutical and research partners, we&#39;re building a robust pipeline of innovative treatments.

Shaohong Liang

Director, Technology Development & Licensing at Memorial Sloan Kettering Cancer Center

Imke Ehlers Surur

Vice President of Nonclincal Research and Development at Abpro

Shaun Murphy

Scientist at Eisai Research Institute

Zuzana Dostalova

Abpro

Please find Cohen & Company Capital Markets (CCM's) quarterly update below. We are seeing dramatic improvement in DeSPAC performance for recent closed deals in addition to green shoots in the traditional IPO markets. CCM had a great start to the year with 17 announced or closed De-SPACs in Q1. Announced Deals: Webull Financial and SK Growth Opportunities Corporation (SKGR) XCF Global Capital Inc. and Focus Impact Partners (BHAC) Hunch Mobility and Direct Selling Acquisition Corp. (DSAQ) Abpro and Atlantic Coastal Acquisition (ACAB) Perception Capital Partners and @RBio Energy (PFTA) ShoulderUp and See ID (SUAC) Closed Deals: Andretti Acquisition Corp. (NYSE:WNNR) and Zapata AI (ZPTA) SIZZLE Acquisition Corp. (NASDAQ: "SZZL") and Critical Metals Corp. (CRML) Two and LatAm Logistic Properties, S.A. (LPA) Concord Acq III and GCT Semiconductor (GCTS) HCM Acquisition Co and Murano (MRNO) ESGEN Acquisition Corporation and Sunergy (ZEO) Semper Paratus and TEVOGEN BIO (TVGN) Phoenix Biotech Ltd. and CERo Therapeutics, Inc. (CERO) Newcourt Acq Corp and Psyence Group (PBM) Chenghe Acq Corp and TCO (SELX) DHC Acq and BEN AI (BNAI)

Dan Nash

Viewport Meta

IPhone / Mobile Compatible

Apple Mobile Web Clips Icon

Google Font API

WordPress

Organization Schema

Sitelinks Search Box

Yoast WordPress SEO Plugin

Yoast Plugins

Yoast SEO Premium

SVP Corporate Development and General Counsel

Christian Zapf

Chairman, CEO

Ian Chan

Chief Medical Officer

Robert Markelewicz

Vice President, Clinical Operations & Head of Program Management

Gifty Awo

Vice President Legal Affairs and Head of IP

Grace Law

SVP, Head of China Business Development

John Xu

Vice President, Human Resources

Susan Fairman

Marketing Director

cole Vanness

Director, Head of Antibody Engineering

James Lulo

Director of Corporate Development

Mengsha Wang

Eugene Cha

CEO & CO-FOUNDER

SVP OF STRATEGIC ALLIANCES

Chairman & CEO

Robert J. Markelewicz

CMO & SVP

Companies With Fewer Than 1000 Employees (Top 10K)

East Coast Companies With More Than 10 Employees (Top 10K)

Health Diagnostics Companies With Less Than $10M in Revenue (Top 10K)

New England Companies With Fewer Than 1000 Employees (Top 10K)

Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide.  As a pioneer of industrial biochemistry and an emerging leader in the reagents field, they have developed a proprietary technology platform that allows for faster, more efficient production of recombinant proteins and antibodies.  As a result, Abpro delivers superior quality products at industry-leading speeds.

Abpro leveraging these platforms, both independently and through collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. The DiversImmune platform enables the generation of novel antibodies and next-generation antibody therapies.

Venture Round - Abpro

Computer and Software Services and Scientific Services

Woburn

Massachusetts

United States

North America

Abpro Announces Closing of Business Combination with Atlantic Coastal Acquisition Corp. II

Abcuro Announces Participation in Upcoming Investor Conferences

Celltrion, Cyron ink $882M deal for polyspecific antibodies

Portage Fintech Acquisition Changes Name to Perception ...

Antibody maker Abpro to go public via SPAC deal

Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO

Abpro gives it another go, this time with a SPAC

Biotechnology company Abpro to merge with SPAC Atlantic Coastal Acquisition

Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II

Age-Related Macular Degeneration Market to Grow Rapidly ...

Abpro develops antibody therapeutics using DiversImmune® and MultiMab™ platforms to create bi- and multi-specific antibodies for various diseases.

This platform generates high affinity and high specificity antibodies against difficult therapeutic targets.

This platform constructs therapeutic candidates by combining antibodies into bi- and multi-specific formats to enhance efficacy and safety.

A tetravalent bispecific antibody format designed for T-cell engagement, offering bivalent binding to tumor antigens, Fc modification, and flexible configurations for safety and efficacy.

South Korea

Asia

India

Serbia

Europe

HTML5

F5 NGINX

Vimeo

jQuery

Amazon EC2

Google Analytics

Adobe Fonts

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 14, 2024 7:57 AM	79afa99f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 14, 2024 7:57 AM	e9040735
crunchbase trigger	general	Nov 14, 2024 7:57 AM	6b51d93b
crunchbase profile	general	Nov 15, 2024 1:40 AM	c2c2a3a9
li profile	general	Nov 14, 2024 7:57 AM	34a3e38b
translate crunchbase fundingrounds	general	Nov 15, 2024 2:36 AM	3649cb62
peers	general	Nov 14, 2024 7:57 AM	51ad5eef
news basic	general	Nov 14, 2024 7:57 AM	7d8c952d
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ABPW

COM:ABPRO

Abro Corporation

Last Close

0.08

22/11 21:00

Volume Today

17.55K

Avg: -